Arca
Skip to content
Tools
Tools

B-cell malignancies

Drug research and approvals for B-cell malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 831 studies of B-cell malignancies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 12 drug trials for it since 2013.

  • Recruiting worldwide: 831
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 831 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
Sep 4, 2026Baf_frontier-1, a first-in-human, phase 1 trial to assess safety, tolerability, and preliminary efficacy of LY4152199, a B-cell activation factor receptor…LY4152199Eli LillyPending
Jul 18, 2024A phase I trial of CLIC-2201 for the treatment of relapsed/refractory b cell malignanciesCLIC-2201 / Fludarabine phosphate / CyclophosphamideBC Cancer, Part of The Provincial Health Services AuthorityOngoing
Jun 28, 2024A modular phase I/II open-label dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a…AZD5492AstraZeneca PharmaceuticalsOngoing
Sep 29, 2023First-in-human study to evaluate the safety, pharmacokinetics, and preliminary efficacy of the btk degrader, ABBV-101, in participants with B-cell malignanciesABBV-101AbbVieOngoing
Mar 22, 2023A phase 1/2,open-label,multicenter, dose escalation and cohort expansion study of the safety and efficacy of ANTI-CD19 allogeneic CRISPR-CAS9-engineered t…CTX112CRISPR TherapeuticsPending
Dec 16, 2022A phase 2, open-label, multicentre, basket study evaluating the safety and efficacy of brexucabtagene autoleucel in adults with rare B-cell malignancies…TecartusKite, A Gilead CompanyPending
Nov 2, 2022A first-in-human multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in B-cell…ABBV-319AbbVieOngoing
Jul 28, 2022A phase 1/2, open-label, dose-escalation and -expansion study of the bruton tyrosine kinase targeted protein degrader BGB-16673 in patients with B-cell…Tacabrutideg (BGB-16673)BeOne MedicinesOngoing
May 20, 2022A multicenter, open-label, phase 2 basket study to evaluate the safety and efficacy of mk¿2140 as a monotherapy and in combination in participants with…Zilovertamab vedotin (MK-2140) / Nemtabrutinib (MK-1026)Merck & Co. (MSD)Ongoing
Feb 15, 2022A single arm, open-label, phase 1b trial of epcoritamab in pediatric patients with relapsed/ refractory aggressive matur B-cell neoplasmsEpcoritamab (ABBV-GMMAB-3013) / TocilizumabAbbVieClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.